| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
|
Lancet Neurol
|
2011
|
3.08
|
|
2
|
Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
|
Stroke
|
2008
|
2.90
|
|
3
|
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
|
JAMA
|
2007
|
1.91
|
|
4
|
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
|
N Engl J Med
|
2015
|
1.62
|
|
5
|
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
|
J Am Coll Cardiol
|
2003
|
1.56
|
|
6
|
Neurohormonal activation in acute heart failure: results from VERITAS.
|
Cardiology
|
2011
|
1.51
|
|
7
|
Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
|
Stroke
|
2012
|
1.23
|
|
8
|
Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
|
Acta Neurochir Suppl
|
2013
|
1.07
|
|
9
|
Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome.
|
J Card Fail
|
2009
|
1.02
|
|
10
|
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
|
Am Heart J
|
2005
|
1.01
|
|
11
|
Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
|
Neurocrit Care
|
2010
|
0.95
|
|
12
|
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
|
J Am Coll Cardiol
|
2003
|
0.91
|
|
13
|
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
|
J Am Coll Cardiol
|
2003
|
0.86
|
|
14
|
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
|
Eur J Heart Fail
|
2004
|
0.84
|
|
15
|
Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome.
|
Eur J Heart Fail
|
2005
|
0.81
|
|
16
|
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).
|
Am Heart J
|
2002
|
0.77
|
|
17
|
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
|
Am Heart J
|
2003
|
0.76
|
|
18
|
Is the distinction between intra- and extra-musical meaning implemented in the brain? Comment on "Towards a neural basis of processing musical semantics" by Stefan Koelsch.
|
Phys Life Rev
|
2011
|
0.75
|